COVID-19 in a Severely Immunosuppressed Patient With Life-Threatening Eosinophilic Granulomatosis With Polyangiitis.

Front Immunol 2020 28;11:2086. Epub 2020 Aug 28.

Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Immunosuppressive therapies increase the susceptibility of patients to infections. The current pandemic with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) compels clinicians to develop recommendations for successful clinical management and surveillance of immunocompromised patients at high risk for severe disease progression. With only few case studies published on SARS-CoV-2 infection in patients with rheumatic diseases, we report a 25-year-old male who developed moderate coronavirus disease 2019 (COVID-19) with fever, mild dyspnea, and no major complications despite having received high-dose prednisolone, cyclophosphamide, and rituximab for the treatment of highly active, life-threatening eosinophilic granulomatosis with polyangiitis (EGPA).

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2020.02086DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7484740PMC
October 2020

Publication Analysis

Top Keywords

life-threatening eosinophilic
8
eosinophilic granulomatosis
8
granulomatosis polyangiitis
8
published sars-cov-2
4
studies published
4
sars-cov-2 infection
4
case studies
4
infection patients
4
report 25-year-old
4
25-year-old male
4
diseases report
4
rheumatic diseases
4
patients rheumatic
4
progression case
4
disease progression
4
management surveillance
4
clinical management
4
successful clinical
4
recommendations successful
4
surveillance immunocompromised
4

Similar Publications